Argitalpenak (184) RAFAEL ARROYO GONZALEZ argitalpenak

2023

  1. Medical help-seeking intentions among patients with early Alzheimer’s disease

    Frontiers in Psychiatry, Vol. 14

  2. Teriflunomide and Epstein–Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response

    Frontiers in Immunology, Vol. 14

  3. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  4. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Awareness of Diagnosis in Persons with Early-Stage Alzheimer’s Disease: An Observational Study in Spain

    Neurology and Therapy, Vol. 11, Núm. 3, pp. 1183-1192

  2. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  3. Epstein-Barr Virus Load Correlates with Multiple Sclerosis-Associated Retrovirus Envelope Expression

    Biomedicines, Vol. 10, Núm. 2

  4. Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study

    Frontiers in Immunology, Vol. 13

  5. High prevalence of intrathecal IgA synthesis in multiple sclerosis patients

    Scientific Reports, Vol. 12, Núm. 1

  6. Mitochondrial Impairments in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients

    Biology, Vol. 11, Núm. 11

  7. Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease

    Journal of Alzheimer's disease : JAD, Vol. 90, Núm. 2, pp. 719-726

  8. Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 8, Núm. 4

  9. Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-β

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years

    Multiple Sclerosis and Related Disorders, Vol. 49

  2. Anti-Human Herpesvirus 6 A/B Antibodies Titers Correlate With Multiple Sclerosis-Associated Retrovirus Envelope Expression

    Frontiers in Immunology, Vol. 12

  3. Evolution of antibody titres against Epstein–Barr virus and human herpesvirus 6A/B and expression of multiple sclerosis-associated retrovirus in the serum of pregnant multiple sclerosis patients

    Scientific Reports, Vol. 11, Núm. 1

  4. Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment

    Frontiers in Immunology, Vol. 12

2020

  1. A cyp51b mutation contributes to azole resistance in aspergillus fumigatus

    Journal of Fungi, Vol. 6, Núm. 4, pp. 1-16

  2. Acetate correlates with disability and immune response in multiple sclerosis

    PeerJ, Vol. 8

  3. Hypomimia in Parkinson's Disease: What Is It Telling Us?

    Frontiers in Neurology, Vol. 11